Subunit-dependent inhibition and potentiation of 5-HT3 receptor by the anticancer drug, topotecan

Journal of Neurochemistry

Volumn 125, Issue 1, 2013, Pages 7-15

  Nakamura, Yukiko ^a   Ishida, Yusuke ^a   Yamada, Takahiro ^a   Kondo, Makoto ^a   Shimada, Shoichi ^a  

^a OSAKA UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

Author keywords

5 HT3A; 5 HT3B; anticancer; modulator; subunit dependent; topotecan

Indexed keywords

4 AMINOBUTYRIC ACID; CALCIUM CHANNEL; CHLORDIAZEPOXIDE; GLYCINE RECEPTOR; ION CHANNEL; IRINOTECAN; LIGAND GATED ION CHANNEL; POTASSIUM CHANNEL; SEROTONIN; SEROTONIN 3 RECEPTOR; SEROTONIN RECEPTOR; SODIUM CHANNEL; TOPOTECAN;

ARTICLE; DRUG MECHANISM; DRUG POTENTIATION; DRUG STRUCTURE; HUMAN; NAUSEA; NAUSEA AND VOMITING; PRIORITY JOURNAL; TREATMENT RESPONSE; VOLTAGE CLAMP; VOMITING;

ANIMALS; ANTINEOPLASTIC AGENTS; FEMALE; HUMANS; MUTATION; OOCYTES; PATCH-CLAMP TECHNIQUES; POLYMORPHISM, GENETIC; PROTEIN SUBUNITS; RECEPTORS, SEROTONIN, 5-HT3; SEROTONIN 5-HT3 RECEPTOR AGONISTS; SEROTONIN 5-HT3 RECEPTOR ANTAGONISTS; TOPOTECAN; XENOPUS LAEVIS;

EID: 84875237433     PISSN: 00223042     EISSN: 14714159     Source Type: Journal    
DOI: 10.1111/jnc.12146     Document Type: Article

References (40)

1. Andreopoulou E., Chen T., Liebes L., Curtin J., Blank S., Wallach R., Hochster H., and, Muggia F., (2011) Phase 1/pharmacology study of intraperitoneal topotecan alone and with cisplatin: potential for consolidation in ovarian cancer. Cancer Chemother. Pharmacol. 68, 457-463.
2. Barrera N. P., Herbert P., Henderson R. M., Martin I. L., and, Edwardson J. M., (2005) Atomic force microscopy reveals the stoichiometry and subunit arrangement of 5-HT3 receptors. Proc. Natl Acad. Sci. USA 102, 12595-12600.
3. Billio A., Morello E., and, Clarke M. J., (2010) Serotonin receptor antagonists for highly emetogenic chemotherapy in adults. Cochrane Database Syst. Rev. Issue 1, CD006272.
4. Brady C. A., Stanford I. M., Ali I., Lin L., Williams J. M., Dubin A. E., Hope A. G., and, Barnes N. M., (2001) Pharmacological comparison of human homomeric 5-HT3A receptors versus heteromeric 5-HT3A/3B receptors. Neuropharmacology 41, 282-284.
5. Champaneria S., Costall B., Naylor R. J., and, Robertson D. W., (1992) Identification and distribution of 5-HT3 recognition sites in the rat gastrointestinal tract. Br. J. Pharmacol. 106, 693-696.
6. Das P., and, Dillon G. H., (2003) The 5-HT3B subunit confers reduced sensitivity to picrotoxin when co-expressed with the 5-HT3A receptor. Brain Res. Mol. Brain Res. 119, 207-212.
7. Davies P. A., (2011) Allosteric modulation of the 5-HT(3) receptor. Curr. Opin. Pharmacol. 11, 75-80.
8. Davies P. A., Pistis M., Hanna M. C., Peters J. A., Lambert J. J., Hales T. G., and, Kirkness E. F., (1999) The 5-HT3B subunit is a major determinant of serotonin-receptor function. Nature 397, 359-363.
9. Forbes C., Shirran L., Bagnall A. M., Duffy S., and, ter Riet G., (2001) A rapid and systematic review of the clinical effectiveness and cost-effectiveness of topotecan for ovarian cancer. Health Technol. Assess. 5, 1-110.
10. Green T., Stauffer K. A., and, Lummis S. C., (1995) Expression of recombinant homo-oligomeric 5-hydroxytryptamine3 receptors provides new insights into their maturation and structure. J. Biol. Chem. 270, 6056-6061.
11. Hapfelmeier G., Tredt C., Haseneder R., Zieglgansberger W., Eisensamer B., Rupprecht R., and, Rammes G., (2003) Co-expression of the 5-HT3B serotonin receptor subunit alters the biophysics of the 5-HT3 receptor. Biophys. J. 84, 1720-1733.
12. Herrstedt J., and, Dombernowsky P., (2007) Anti-emetic therapy in cancer chemotherapy: current status. Basic Clin. Pharmacol. Toxicol. 101, 143-150.
13. Hussy N., Lukas W., and, Jones K. A., (1994) Functional properties of a cloned 5-hydroxytryptamine ionotropic receptor subunit: comparison with native mouse receptors. J. Physiol. 481 (Pt 2), 311-323.
14. Kilpatrick G. J., Jones B. J., and, Tyers M. B., (1989) Binding of the 5-HT3 ligand, [3H]GR65630, to rat area postrema, vagus nerve and the brains of several species. Eur. J. Pharmacol. 159, 157-164.
15. Kobayashi K., Hino M., Fukuoka M., et al,. (2002) Phase I studies of nogitecan hydrochloride for Japanese. Int. J. Clin. Oncol. 7, 177-186.
16. Krieg P. A., and, Melton D. A., (1984) Functional messenger RNAs are produced by SP6 in vitro transcription of cloned cDNAs. Nucleic Acids Res. 12, 7057-7070.
17. Krzywkowski K., Davies P. A., Feinberg-Zadek P. L., Brauner-Osborne H., and, Jensen A. A., (2008) High-frequency HTR3B variant associated with major depression dramatically augments the signaling of the human 5-HT3AB receptor. Proc. Natl Acad. Sci. USA 105, 722-727.
18. Kunimoto T., Nitta K., Tanaka T., Uehara N., Baba H., Takeuchi M., Yokokura T., Sawada S., Miyasaka T., and, Mutai M., (1987) Antitumor activity of 7-ethyl-10-[4-(1-piperidino)-1-piperidino]carbonyloxy-camptothec in, a novel water-soluble derivative of camptothecin, against murine tumors. Cancer Res. 47, 5944-5947.
19. Lester H. A., Dibas M. I., Dahan D. S., Leite J. F., and, Dougherty D. A., (2004) Cys-loop receptors: new twists and turns. Trends Neurosci. 27, 329-336.
20. Lochner M., and, Lummis S. C., (2010) Agonists and antagonists bind to an A-A interface in the heteromeric 5-HT3AB receptor. Biophys. J. 98, 1494-1502.
21. Lovinger D. M., and, White G., (1991) Ethanol potentiation of 5-hydroxytryptamine3 receptor-mediated ion current in neuroblastoma cells and isolated adult mammalian neurons. Mol. Pharmacol. 40, 263-270.
22. Lummis S. C., Beene D. L., Lee L. W., Lester H. A., Broadhurst R. W., and, Dougherty D. A., (2005) Cis-trans isomerization at a proline opens the pore of a neurotransmitter-gated ion channel. Nature 438, 248-252.
23. Maksay G., Thompson S. A., and, Wafford K. A., (2000) Allosteric modulators affect the efficacy of partial agonists for recombinant GABA(A) receptors. Br. J. Pharmacol. 129, 1794-1800.
24. Nakamura Y., Ishida Y., Yamada T., and, Shimada S., (2011) Anticancer drug irinotecan inhibits homomeric 5-HT3A and heteromeric 5-HT3AB receptor responses. Biochem. Biophys. Res. Commun. 415, 416-420.
25. Niesler B., Frank B., Kapeller J., and, Rappold G. A., (2003) Cloning, physical mapping and expression analysis of the human 5-HT3 serotonin receptor-like genes HTR3C, HTR3D and HTR3E. Gene 310, 101-111.
26. Niesler B., Walstab J., Combrink S., Moller D., Kapeller J., Rietdorf J., Bonisch H., Gothert M., Rappold G., and, Bruss M., (2007) Characterization of the novel human serotonin receptor subunits 5-HT3C,5-HT3D, and 5-HT3E. Mol. Pharmacol. 72, 8-17.
27. O'Brien M., Eckardt J., and, Ramlau R., (2007) Recent advances with topotecan in the treatment of lung cancer. Oncologist 12, 1194-1204.
28. Peng L. H., Chen X. Y., and, Wu T. X., (2008) Topotecan for ovarian cancer. Cochrane Database Syst. Rev. Issue 2, CD005589.
29. Pratt G. D., and, Bowery N. G., (1989) The 5-HT3 receptor ligand, [3H]BRL 43694, binds to presynaptic sites in the nucleus tractus solitarius of the rat. Neuropharmacology 28, 1367-1376.
30. Shah D. K., and, Balthasar J. P., (2011) Physiologically based pharmacokinetic model for topotecan in mice. J. Pharmacokinet Pharmacodyn. 38, 121-142.
31. Solt K., Stevens R. J., Davies P. A., and, Raines D. E., (2005) General anesthetic-induced channel gating enhancement of 5-hydroxytryptamine type 3 receptors depends on receptor subunit composition. J. Pharmacol. Exp. Ther. 315, 771-776.
32. Stevens R., Rusch D., Solt K., Raines D. E., and, Davies P. A., (2005) Modulation of human 5-hydroxytryptamine type 3AB receptors by volatile anesthetics and n-alcohols. J. Pharmacol. Exp. Ther. 314, 338-345.
33. Sugai T., Suzuki Y., Sawamura K., Fukui N., Inoue Y., and, Someya T., (2006) The effect of 5-hydroxytryptamine 3A and 3B receptor genes on nausea induced by paroxetine. Pharmacogenomics J. 6, 351-356.
34. Thompson S. A., Wingrove P. B., Connelly L., Whiting P. J., and, Wafford K. A., (2002) Tracazolate reveals a novel type of allosteric interaction with recombinant gamma-aminobutyric acid(A) receptors. Mol. Pharmacol. 61, 861-869.
35. Thompson A. J., Duke R. K., and, Lummis S. C., (2011) Binding sites for bilobalide, diltiazem, ginkgolide, and picrotoxinin at the 5-HT3 receptor. Mol. Pharmacol. 80, 183-190.
36. Tischbirek C. H., Wenzel E. M., Zheng F., et al,. (2012) Use-dependent inhibition of synaptic transmission by the secretion of intravesicularly accumulated antipsychotic drugs. Neuron 74, 830-844.
37. Trattnig S. M., Harpsoe K., Thygesen S. B., Rahr L. M., Ahring P. K., Balle T., and, Jensen A. A., (2012) Discovery of a novel allosteric modulator of 5-HT3 receptors: inhibition and potentiation of cys-loop receptor signaling through a conserved transmembrane intersubunit site. J. Biol. Chem. 287, 25241-25254.
38. Tyers M. B., and, Freeman A. J., (1992) Mechanism of the anti-emetic activity of 5-HT3 receptor antagonists. Oncology 49, 263-268.
39. Walstab J., Hammer C., Bonisch H., Rappold G., and, Niesler B., (2008) Naturally occurring variants in the HTR3B gene significantly alter properties of human heteromeric 5-hydroxytryptamine-3A/B receptors. Pharmacogenet. Genomics 18, 793-802.
40. Yang J., Mathie A., and, Hille B., (1992) 5-HT3 receptor channels in dissociated rat superior cervical ganglion neurons. J. Physiol. 448, 237-256.